文献速递肥胖与代谢综合征糖尿病

GIP与GLP-1联合输注对超重/肥胖男性能量摄入、食欲和能量消耗的影响:随机交叉研究

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
PubMed 文献 · Diabetologia · 2019-01-25

该随机交叉研究在17名超重/肥胖男性中比较了GLP-1、GIP及两者联合输注对能量摄入的影响。结果显示GLP-1输注显著降低能量摄入,而联合GIP并未增强GLP-1的这一效应,GIP单独或联合输注与安慰剂相比无显著差异。

要点

  • GLP-1输注显著降低超重/肥胖男性的自由进食能量摄入。
  • 联合GIP输注未增强GLP-1降低能量摄入的效应。
  • GIP单独输注对能量摄入无显著影响。

核心结论

  • 在超重/肥胖男性中,GLP-1输注降低能量摄入,但同时输注GIP并未增强GLP-1介导的这一效应。

研究设计与样本

  • 随机、双盲、交叉设计,17名超重/肥胖男性完成5个研究日,包括1次50g OGTT和4次等血糖静脉葡萄糖输注(IIGI)分别联合生理盐水、GIP、GLP-1或GIP+GLP-1。

主要发现

  • IIGI+GLP-1期间能量摄入显著低于IIGI+生理盐水(2715 ± 409 vs 4483 ± 568 kJ,均值±SEM,n=17,p=0.014)。
  • IIGI+GIP期间能量摄入为4062 ± 520 kJ,与生理盐水相比无显著差异(p=0.590)。
  • IIGI+GIP+GLP-1期间能量摄入为3875 ± 451 kJ,与生理盐水相比无显著差异(p=0.364)。
  • IIGI+GIP+GLP-1期间能量摄入高于IIGI+GLP-1(p=0.039)。

临床怎么用

  • 研究结果提示,在超重/肥胖男性中联合激活GIP和GLP-1受体未显示对能量摄入的协同抑制效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Glucagon-like peptide 1 (GLP-1) reduces appetite and energy intake in humans, whereas the other incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), seems to have no effect on eating behaviour. Interestingly, studies in rodents have shown that concomitant activation of GIP and GLP-1 receptors may potentiate the satiety-promoting effect of GLP-1, and a novel dual GLP-1/GIP receptor agonist was recently shown to trigger greater weight losses compared with a GLP-1 receptor agonist in individuals with type 2 diabetes. The aim of this study was to delineate the effects of combined GIP and GLP-1 receptor activation on energy intake, appetite and resting energy expenditure in humans. METHODS: We examined 17 overweight/obese men in a crossover design with 5 study days. On day 1, a 50 g OGTT was performed; on the following 4 study days, the men received an isoglycaemic i.v. glucose infusion (IIGI) plus saline (154 mmol/l NaCl; placebo), GIP (4 pmol kg-1 min-1), GLP-1 (1 pmol kg-1 min-1) or GIP+GLP-1 (4 and 1 pmol kg-1 min-1, respectively). All IIGIs were performed in a randomised order blinded for the participant and the investigators. The primary endpoint was energy intake as measured by an ad libitum meal after 240 min. Secondary endpoints included appetite ratings and resting energy expenditure, as well as insulin, C-peptide and glucagon responses. RESULTS: Energy intake was significantly reduced during IIGI+GLP-1 compared with IIGI+saline infusion (2715 ± 409 vs 4483 ± 568 kJ [mean ± SEM, n = 17], p = 0.014), whereas there were no significant differences in energy intake during IIGI+GIP (4062 ± 520 kJ) or IIGI+GIP+GLP-1 (3875 ± 451 kJ) infusion compared with IIGI+saline (p = 0.590 and p = 0.364, respectively). Energy intake was higher during IIGI+GIP+GLP-1 compared with IIGI+GLP-1 infusion (p = 0.039). CONCLUSIONS/INTERPRETATION: While GLP-1 infusion lowered energy intake in overweight/obese men, simultaneous GIP infusion did not potentiate this GLP-1-mediated effect. TRIAL REGISTRATION: ClinicalTrials.gov NCT02598791 FUNDING: This study was supported by grants from the Innovation Fund Denmark and the Vissing Foundation.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bergmann NC, Lund A, Gasbjerg LS, et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia. 2019. PMID: 30683945. doi:10.1007/s00125-018-4810-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。